f The Role of Inflammatory Biomarkers in the Pre-Biopsy Risk Stratification of Patients with Suspicious MRI Lesions of the Prostate: Where Should We Head?

References

1. BergengrenO. PekalaK.R. MatsoukasK. FainbergJ. MungovanS.F. BrattO. BrayF. BrawleyO. LuckenbaughA.N. MucciL. MorganT.M. CarlssonS.V. 2022 Update on prostate cancer epidemiology and risk factors - A systematic review.Eur. Urol.202384219120610.1016/j.eururo.2023.04.021 37202314
   [Google Scholar]
2. YinX. XiaoY. LiF. QiS. YinZ. GaoJ. Prognostic role of neutrophil-to-lymphocyte ratio in prostate cancer.Medicine (Baltimore)2016953e254410.1097/MD.0000000000002544 26817900
   [Google Scholar]
3. WoodrumD.A. KawashimaA. GornyK.R. MynderseL.A. Targeted prostate biopsy and MR-guided therapy for prostate cancer.Abdom. Radiol. (N.Y.)201641587788810.1007/s00261‑016‑0681‑3 26907717
   [Google Scholar]
4. RajwaP. HuebnerN.A. HostermannD.I. GrossmannN.C. SchuettfortV.M. KornS. QuhalF. KönigF. MostafaeiH. LaukhtinaE. MoriK. MotlaghR.S. YanagisawaT. AydhA. BryniarskiP. PradereB. ParadyszA. BaltzerP.A. GrubmüllerB. ShariatS.F. Evaluation of the predictive role of blood-based biomarkers in the context of suspicious prostate MRI in patients undergoing prostate biopsy.J. Pers. Med.20211111123110.3390/jpm11111231 34834583
   [Google Scholar]
5. CornfordP. van den BerghR.C.N. BriersE. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update.Eur. Urol.202486214816310.1016/j.eururo.2024.03.027
   [Google Scholar]
6. GiannakodimosI. Urinary miRNAs as diagnostic biomarkers for prostatic cancer: Current dilemmas and novel potential role for a digital rectal examination.Curr. Med. Chem.202229254311431310.2174/0929867329666220118101733 35040397
   [Google Scholar]
7. ZiogouA. GiannakodimosA. GiannakodimosI. The role of urinary miRNAs in the diagnosis, management and follow-up of prostatic cancer.MicroRNA2023122838610.2174/2211536612666230324102850 36999432
   [Google Scholar]
8. GiannakodimosI. Urinary miRNAs and prostate cancer: Is there a crossover point eventually, and where should we head?Curr. Med. Chem.202431416733673410.2174/0109298673304111240325062717 38571346
   [Google Scholar]
9. GholamiN. HaghparastA. AlipourfardI. NazariM. Prostate cancer in omics era.Cancer Cell Int.202222127410.1186/s12935‑022‑02691‑y 36064406
   [Google Scholar]
10. CornfordP. van den BerghR.C.N. BriersE. Van den BroeckT. BrunckhorstO. DarraughJ. EberliD. De MeerleerG. De SantisM. FarolfiA. GandagliaG. GillessenS. GrivasN. HenryA.M. LardasM. van LeendersG.J.L.H. LiewM. Linares EspinosE. OldenburgJ. van OortI.M. Oprea-LagerD.E. PloussardG. RobertsM.J. RouvièreO. SchootsI.G. SchoutenN. SmithE.J. StranneJ. WiegelT. WillemseP.P.M. TilkiD. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer—2024 update. Part I: Screening, diagnosis, and local treatment with curative intent.Eur. Urol.202486214816310.1016/j.eururo.2024.03.027 38614820
    [Google Scholar]
11. WeiJ.T. BarocasD. CarlssonS. CoakleyF. EggenerS. EtzioniR. FineS.W. HanM. KimS.K. KirkbyE. KonetyB.R. MinerM. MosesK. NissenbergM.G. PintoP.A. SalamiS.S. SouterL. ThompsonI.M. LinD.W. Early detection of prostate cancer: AUA/SUO guideline Part II: Considerations for a prostate biopsy.J. Urol.20232101546310.1097/JU.0000000000003492 37096575
    [Google Scholar]
12. WangL. LiX. LiuM. ZhouH. ShaoJ. Association between monocyte-to-lymphocyte ratio and prostate cancer in the U.S. population: A population-based study.Front. Cell Dev. Biol.202412137273110.3389/fcell.2024.1372731 38645410
    [Google Scholar]
13. KaynarM. YildirimM.E. GulM. KilicO. CeylanK. GoktasS. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio.Cancer Biomark.201515331732310.3233/CBM‑150458 25586096
    [Google Scholar]
14. SunJ. ZhangZ. OuYangJ. A novel nomogram combined PIRADS v2 and neutrophil-to-lymphocyte ratio to predict the risk of clinically significant prostate cancer in men with PSA < 10 ng/ml at first biopsy.Urol. Oncol.202038540140910.1016/j.urolonc.2019.12.006 31870724
    [Google Scholar]